Bladder Cancer

Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification. July 30, 2026

Germline testing in urothelial cancer: A narrative review of evidence, guidelines, and testing frameworks. July 30, 2026

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. July 29, 2026

Ideal candidates for bladder preservation in muscle-invasive bladder cancer. July 28, 2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. July 28, 2026

Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer. July 27, 2026

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. July 24, 2026

BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guérin Delivery for High-risk Non-muscle-invasive Bladder Cancer. July 24, 2026

Postoperative Management After Pathological Complete Response to Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: An Exploratory Reconstructed Individual Patient Data Analysis. July 23, 2026

Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. July 22, 2026

Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. July 30, 2026

Unveiling the Paradoxical Tumor-Suppressive Role of CCL2/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy. July 29, 2026

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology July 28, 2026

Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan. July 28, 2026

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications - Beyond the Abstract July 27, 2026

Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. July 27, 2026

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials. July 24, 2026

Impact of age on the effectiveness of intravesical Bacillus Calmette‑Guérin and gemcitabine/docetaxel in treatment-naïve high-risk non‑muscle‑invasive bladder cancer. July 23, 2026

Network meta-analysis of immune checkpoint inhibitors in BCG-naïve, high-risk non-muscle-invasive bladder cancer. July 23, 2026

Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications. July 22, 2026

Page 1 of 608